BioMedNewsBreaks Archive - Page 46 of 250

MondayFeb 10, 2025 1:39 pm

BioMedNewsBreaks — CNS Pharmaceuticals Inc. (NASDAQ: CNSP) CEO to Present at BIO CEO & Investor Conference

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company focused on developing treatments for brain and central nervous system cancers, will participate in the BIO CEO & Investor Conference in New York on Feb. 10-11, 2025. CEO John Climaco is scheduled to present on Feb. 10 at 1:15 p.m. ET in the Royale Room. Management will also be available for one-on-one meetings, with scheduling available through the BIO CEO attendee portal. To view the full press release, visit https://ibn.fm/alIXv About CNS Pharmaceuticals Inc. CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary…

MondayFeb 10, 2025 12:57 pm

BioMedNewsBreaks — Quantum BioPharma Ltd. (NASDAQ: QNTM) Engages Enterprise Canada, Empire Market Ventures for PR, Investor Awareness

Quantum BioPharma (NASDAQ: QNTM) has retained Enterprise Canada Inc. and Empire Market Ventures, LLC to lead its public relations and investor awareness efforts. Enterprise, engaged indefinitely, will develop the company’s media strategy, while Empire, engaged for three months starting Feb. 7, 2025, will focus on investor marketing and outreach. The company highlighted progress on its key products, including unbuzzd™, a rapid alcohol detoxification beverage set for Q1 2025 availability, rekvry™, an alcohol misuse treatment, and LUCID-21-302, a potential multiple sclerosis treatment moving toward Phase 2 trials. To view the full press release, visit https://ibn.fm/BxkjT About Quantum BioPharma Ltd. Quantum BioPharma is a…

FridayFeb 07, 2025 10:35 am

BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) CEO to Present at Oppenheimer Healthcare Conference

Annovis Bio (NYSE: ANVS) a late-stage clinical drug platform company developing therapies for neurodegenerative diseases, announced that CEO Maria Maccecchini, Ph.D., will present at Oppenheimer’s 35th Annual Healthcare Life Sciences Conference on Feb. 11, 2025, from 12:40 to 1:10 p.m. ET. The virtual presentation will cover the company’s progress on its pivotal Phase 3 trial for early Alzheimer’s disease and strategic plans for a New Drug Application for buntanetap. The conference gathers industry leaders and investors to discuss key innovations and market trends in healthcare and life sciences. To view the full press release, visit https://ibn.fm/VFXm1 About Annovis Bio Inc.…

ThursdayFeb 06, 2025 1:40 pm

BioMedNewsBreaks – BioAdaptives Inc. (BDPT) Announces Board Appointment of UFC Senior Executive Reed Harris

BioAdaptives (OTC: BDPT), a leading biotechnology company focused on innovative health and wellness solutions, has announced the appointment of Reed Harris to its board of advisors. Harris, the senior VP of athlete development and marketing at the Ultimate Fighting Championship (“UFC”) in Las Vegas, brings decades of experience in leadership, athlete development and business management, as well as a proven commitment to driving innovation and excellence. “Reed’s exceptional leadership, business acumen and dedication to athlete development and community service align perfectly with our mission to deliver innovative health and wellness solutions,” said Jim Keener, CEO of BioAdaptives. “His deep experience…

ThursdayFeb 06, 2025 9:45 am

BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Enrolls First Patients in Phase 3 Alzheimer’s Trial

Annovis Bio (NYSE: ANVS) announced that the first two patients have been enrolled in its pivotal Phase 3 trial evaluating buntanetap for early Alzheimer’s disease. The randomized, placebo-controlled study will assess the drug’s symptomatic and potential disease-modifying effects over 18 months. Following positive Phase 2/3 results, the trial received FDA approval and aims to enroll over 750 participants across approximately 100 U.S. sites. The company recently secured $21 million in funding to support the initial six-month phase, with the remaining study expected to be funded through warrant exercises. To view the full press release, visit https://ibn.fm/MxaD5 About Annovis Bio Inc.…

WednesdayFeb 05, 2025 3:00 pm

BioMedNewsBreaks — Astiva Health’s Focus on Multilingual Support, Tailored Solutions Driving Its Success

Astiva Health now serves more than 30,000 members, an increase that reflects the growing demand for the company’s unique, culturally aligned health care model. “The increase in membership comes as Astiva earned a prestigious 4-star CMS rating for 2025, placing it among the top-rated Medicare Advantage providers in California,” reads a recent article. “This membership surge reflects the growing demand for Astiva’s culturally aligned health care model. The emphasis on multilingual support and culturally responsive services has made the company a leader in inclusive health care. In addition, partnerships with local businesses and activity centers have enabled Astiva to foster meaningful…

WednesdayFeb 05, 2025 11:56 am

BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Closes $21M Public Offering to Advance Alzheimer’s Drug Development

Annovis Bio (NYSE: ANVS), a late-stage clinical drug company focused on neurodegenerative diseases, announced the closing of its underwritten public offering, raising $21 million in gross proceeds. The offering included 5.25 million shares of common stock and warrants at a combined price of $4.00 per share, with warrants exercisable at $5.00 per share for five years. The company plans to use the funds primarily for the continued Phase 3 development of its lead Alzheimer’s drug, Buntanetap, as well as for working capital and corporate purposes. ThinkEquity acted as the sole book-running manager. To view the full press release, visit https://ibn.fm/rOYgn…

TuesdayFeb 04, 2025 3:07 pm

BioMedNewsBreaks — BriaCell Therapeutics Corp. (NASDAQ: BCTX) (TSX: BCT) Announces Pricing of $3.05M Public Offering

BriaCell (NASDAQ: BCTX, BCTXW) (TSX: BCT), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, has announced the pricing of a best-efforts public offering of 762,500 common shares, each at a public offering price of $4.00. The company expects $3.05 million in total gross proceeds from the offering, of which it intends to use the net for working capital, general corporate purposes, and the advancement of business objectives. Subject to the satisfaction of customary conditions, the offering is expected to close on Feb. 5, 2025. ThinkEquity is acting as the sole placement agent for the offering. To…

TuesdayFeb 04, 2025 10:46 am

BioMedNewsBreaks — Quantum BioPharma Ltd. (NASDAQ: QNTM) Reports Positive Clinical Trial Results for unbuzzd™

Quantum BioPharma (NASDAQ: QNTM) announced the successful completion of a clinical trial demonstrating that its dietary supplement, unbuzzd™, significantly accelerates alcohol metabolism and reduces symptoms of intoxication and hangovers. The double-blind, placebo-controlled study showed that unbuzzd™ lowered blood alcohol concentration by over 40% faster within 30 minutes compared to placebo, while improving alertness and stabilizing heart rate and blood pressure. Participants also reported reduced mental fatigue and hangover symptoms without adverse side effects. Quantum BioPharma CEO Zeeshan Saeed highlighted unbuzzd™ as a breakthrough in promoting safe and responsible alcohol consumption. To view the full press release, visit https://ibn.fm/jKWGf About Quantum…

TuesdayFeb 04, 2025 9:50 am

BioMedNewsBreaks – HealthLynked Corp. Highlights 2024 Achievements, Sets Vision for Future Growth

HealthLynked (OTCQB: HLYK) released its Annual Shareholder Letter, detailing key advancements in 2024 and outlining its strategic priorities for 2025. The company launched ARI, an AI-powered healthcare guidance tool, expanded its telemedicine services nationwide, introduced a concierge healthcare service, and implemented a discount prescription drug program. CEO Dr. Dent emphasized HealthLynked’s focus on scaling its platform through strategic partnerships, innovative marketing, and expanded service offerings. Looking ahead, the company aims to enhance patient care management, broaden healthcare access, and leverage patient data for medical research and improved outcomes. To view the full press release, visit https://ibn.fm/RttDI About HealthLynked Corp. HealthLynked…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

BioMedNewsBreaks

BioMedNewsBreaks — CNS Pharmaceuticals Inc. (NASDAQ: CNSP) CEO to Present at BIO CEO & Investor Conference

BioMedNewsBreaks — Quantum BioPharma Ltd. (NASDAQ: QNTM) Engages Enterprise Canada, Empire Market Ventures for PR, Investor Awareness

BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) CEO to Present at Oppenheimer Healthcare Conference

BioMedNewsBreaks – BioAdaptives Inc. (BDPT) Announces Board Appointment of UFC Senior Executive Reed Harris

BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Enrolls First Patients in Phase 3 Alzheimer’s Trial

BioMedNewsBreaks — Astiva Health’s Focus on Multilingual Support, Tailored Solutions Driving Its Success

BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Closes $21M Public Offering to Advance Alzheimer’s Drug Development

BioMedNewsBreaks — BriaCell Therapeutics Corp. (NASDAQ: BCTX) (TSX: BCT) Announces Pricing of $3.05M Public Offering

BioMedNewsBreaks — Quantum BioPharma Ltd. (NASDAQ: QNTM) Reports Positive Clinical Trial Results for unbuzzd™

BioMedNewsBreaks – HealthLynked Corp. Highlights 2024 Achievements, Sets Vision for Future Growth

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search